JNJ

227.58

+1.12%↑

ABT

93.81

+1.03%↑

MDT

81.87

-1.27%↓

114.85

-0.62%↓

VEEV

158.41

-1.09%↓

JNJ

227.58

+1.12%↑

ABT

93.81

+1.03%↑

MDT

81.87

-1.27%↓

114.85

-0.62%↓

VEEV

158.41

-1.09%↓

JNJ

227.58

+1.12%↑

ABT

93.81

+1.03%↑

MDT

81.87

-1.27%↓

114.85

-0.62%↓

VEEV

158.41

-1.09%↓

JNJ

227.58

+1.12%↑

ABT

93.81

+1.03%↑

MDT

81.87

-1.27%↓

114.85

-0.62%↓

VEEV

158.41

-1.09%↓

JNJ

227.58

+1.12%↑

ABT

93.81

+1.03%↑

MDT

81.87

-1.27%↓

114.85

-0.62%↓

VEEV

158.41

-1.09%↓

Home・Akciju saraksts・Emergent BioSolutions Inc

Emergent BioSolutions Inc

Slēgts

SektorsVeselības aprūpe

8.22 2.11

Pirkt Pārdot

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

8.05

Max

8.22

Galvenie mērījumi
By Trading Economics
Ienākumi	-106M -55M
Pārdošana	-82M 149M
P/E Sektora vidējais	8.979 60.328
EPS	-0.43
Peļņas marža	-36.718
Darbinieki	900
EBITDA	-89M 6.9M

Rekomendācijas
By TipRanks
Rekomendācijas	Pirkt
Prognoze 12 mēnešiem	+49.44% upside

Dividendes
By Dow Jones
Nākamie ieņēmumi	2026. g. 30. apr.

Tirgus statistika
By TradingEconomics
Tirgus kapitalizācija	-152M 432M
Iepriekšējā atvēršanas cena	6.11
Iepriekšējā slēgšanas cena	8.22

Ziņu noskaņojums

By Acuity

15%

85%

31 / 348 Rangs Healthcare

Tehniskais rādītājs

By Trading Central

Pārliecība

Bullish Evidence

4.95 / N/A Atbalsts un pretestība

Emergent BioSolutions Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 27. apr. 23:15 UTC

Galvenie ziņu notikumi

U.K. Consumers Pay Less But Full Impact of Mideast War to Be Seen

2026. g. 27. apr. 23:08 UTC

Peļņas

Galvenie tirgus virzītāji

LendingClub Shares Gain on 1Q Profit, Revenue Beat

2026. g. 27. apr. 23:58 UTC

Peļņas

Samsung SDI 1Q Net Profit Beat FactSet-Compiled Consensus

2026. g. 27. apr. 23:58 UTC

Peļņas

Samsung SDI 1Q Net KRW56.10B Vs. Loss KRW216.00B >006400.SE

2026. g. 27. apr. 23:56 UTC

Peļņas

Samsung SDI 1Q Oper Loss KRW155.60B Vs. Loss KRW434.10B >006400.SE

2026. g. 27. apr. 23:56 UTC

Peļņas

Samsung SDI 1Q Rev KRW3.576T Vs. KRW3.177T >006400.SE

2026. g. 27. apr. 23:48 UTC

Tirgus saruna

Nikkei May Remain Rangebound Amid Uncertainty Over Iran Conflict -- Market Talk

2026. g. 27. apr. 23:42 UTC

Tirgus saruna

Australian Consumer Confidence Making a Slow Come Back -- Market Talk

2026. g. 27. apr. 23:34 UTC

Tirgus saruna

Galvenie ziņu notikumi

Gold Edges Higher as Investors Assess Iran's Proposal to U.S. -- Market Talk

2026. g. 27. apr. 23:30 UTC

Tirgus saruna

Australia's NDIS Could Lose 'Social Licence' If Not Reined In -- Market Talk

2026. g. 27. apr. 23:08 UTC

Tirgus saruna

Polymetals's Revenue Outlook 'Extraordinary' for a Small-Cap Stock -- Market Talk

2026. g. 27. apr. 23:02 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

2026. g. 27. apr. 23:02 UTC

Tirgus saruna

Warsh Will Probably Lean a Bit More Dovish Than Powell -- Market Talk

2026. g. 27. apr. 22:42 UTC

Tirgus saruna

BOJ Expected to Keep Rates On Hold; Guidance to Skew Hawkish -- Market Talk

2026. g. 27. apr. 22:10 UTC

Peļņas

Haier Smart Home: Results Also Weighed by Weak Demand in China-U.S. Markets >600690.SH

2026. g. 27. apr. 22:09 UTC

Peļņas

Haier Smart Home: Increase in Tariff Costs, Extreme Weather Conditions Hurt Results >600690.SH

2026. g. 27. apr. 22:09 UTC

Peļņas

Haier Smart Home 1Q Net CNY4.65B Vs. Net CNY5.49B >600690.SH

2026. g. 27. apr. 22:09 UTC

Peļņas

Haier Smart Home 1Q Rev CNY73.69B Vs. CNY79.12B >600690.SH

2026. g. 27. apr. 21:56 UTC

Peļņas

Tsingtao Brewery: Cost Controls Among Factors Supporting Results >0168.HK

2026. g. 27. apr. 21:55 UTC

Peļņas

Tsingtao Brewery 1Q Net CNY1.80B Vs. Net CNY1.71B >0168.HK

2026. g. 27. apr. 21:55 UTC

Peļņas

Tsingtao Brewery 1Q Rev CNY10.29B Vs. CNY10.45B >0168.HK

2026. g. 27. apr. 21:44 UTC

Peļņas

Tianqi Lithium: Higher Demand for Products From EV Sector Also Boosted Financial Performance >002466.SZ

2026. g. 27. apr. 21:43 UTC

Peļņas

Tianqi Lithium: Increase in Average Selling Prices of Major Lithium Products Supported Results >002466.SZ

2026. g. 27. apr. 21:41 UTC

Peļņas

Tianqi Lithium 1Q Rev CNY5.13B Vs. CNY2.58B >002466.SZ

2026. g. 27. apr. 21:41 UTC

Peļņas

Tianqi Lithium 1Q Net CNY1.88B Vs. Net CNY104.27M >002466.SZ

2026. g. 27. apr. 20:50 UTC

Tirgus saruna

Tech, Media & Telecom Roundup: Market Talk

2026. g. 27. apr. 20:50 UTC

Tirgus saruna

Galvenie ziņu notikumi

Basic Materials Roundup: Market Talk

2026. g. 27. apr. 20:50 UTC

Tirgus saruna

Iegādes, apvienošanās, pārņemšana

Financial Services Roundup: Market Talk

2026. g. 27. apr. 20:50 UTC

Tirgus saruna

Health Care Roundup: Market Talk

2026. g. 27. apr. 20:39 UTC

Peļņas

Nucor: Operating Segments Earnings Growth Driven by Trade Policies That Continue to Reduce Flood of Unfairly Traded Imports Into U.S. >NUE

Salīdzinājums

Cenas izmaiņa

Emergent BioSolutions Inc Prognoze

Cenas mērķis

By TipRanks

49.44% augšup

Prognoze 12 mēnešiem

Vidējais 12 USD 49.44%

Augstākais 12 USD

Zemākais 12 USD

Pamatojoties uz 1 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Emergent BioSolutions Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt

1 ratings

Pirkt

Turēt

Pārdot

Pamatojoties uz 1 analītiķiem, kas pēdējo 3 mēnešu laikā snieguši akciju vērtējumus instrumentam Emergent BioSolutions Inc — pēdējo 3 mēnešu laikā.

Tehniskais rādītājs

By Trading Central

4.95 / N/AAtbalsts un pretestība

Recent bullish events outweigh bearish events.

Bearish events outweigh bullish events.

Noskaņojums

By Acuity

31 / 348 Rangs Veselības aprūpe

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

Par Emergent BioSolutions Inc

Emergent BioSolutions Inc., a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax. It also provides ACAM2000, a smallpox vaccine; CNJ-016 to address complications from smallpox vaccination; TEMBEXA for the treatment of smallpox disease caused by variola virus in adult and pediatric patients; BAT for the treatment of symptomatic botulism; Ebanga for the treatment of Ebola; Reactive Skin Decontamination Lotion Kit to remove or neutralize chemical warfare agents from the skin; Trobigard, a atropine sulfate obidoxime chloride auto-injector. In addition, the company is developing CGRD-001 for the treatment of poisoning by organophosphorus nerve agents or organophosphorus compounds; EBS-LASV to prevent Lassa fever; EBS-MARV to prevent Marburg virus disease; EBS-SUDV to prevent Sudan virus disease; Pan-Ebola mAbs for the treatment of ebola virus; SIAN Antidote for initial treatment of certain or suspected acute cyanide poisoning; UniFlu for immunity against influenza A and B viruses; and WEVEE-VLP for equine encephalitis virus infections. Further, it provides contract development and manufacturing services comprising drug substance and product manufacturing, and packaging, as well as technology transfer, process, and analytical development services. The company was incorporated in 1998 and is headquartered in Gaithersburg, Maryland.